In 2012, the U.S. Food and Drug Administration approved the first CF transmembrane conductance regulator (CFTR) modulator, the combination therapy ivacaftor/lumacaftor (Orkambi), for treating CF patients with the F508del gene mutation, which has significantly improved survival in CF patients. The gene discussed is CFTR; the disease is cystic fibrosis.